

UCSF

UC San Francisco Previously Published Works

Title

Divergent synthesis of organophosphate [11C]VX- and [11C]Sarin-surrogates from a common set of starting materials.

Permalink

<https://escholarship.org/uc/item/33n2c0s1>

Authors

Hayes, Thomas
Blecha, Joseph
Thompson, Charles
[et al.](#)

Publication Date

2019-09-01

DOI

10.1016/j.apradiso.2019.05.033

Peer reviewed



Published in final edited form as:

Appl Radiat Isot. 2019 September ; 151: 182–186. doi:10.1016/j.apradiso.2019.05.033.

Divergent Synthesis of Organophosphate [¹¹C]VX- and [¹¹C]Sarin-Surrogates from a Common Set of Starting Materials

Thomas R. Hayes^a, Joseph E. Blecha^a, Charles M. Thompson^b, John M. Gerdes^b, Henry F. VanBrocklin^a

^aDepartment of Radiology and Biomedical Imaging, University of California – San Francisco, 185 Berry St. Suite 350, San Francisco, CA 94107, United States

^bDepartment of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, MT 59812, United States

Abstract

Radiolabeled 1-[¹¹C]ethyl, 4-nitrophenyl methylphosphonate (VX-surrogate) and 2-[¹¹C]-propanyl, 4-nitrophenyl methylphosphonate (sarin surrogate) were developed as organophosphate (OP) tracers. The [¹¹C]ethyl- and [¹¹C]isopropyl-iodide radiolabeled synthons were obtained by temperature controlled, in loop reactions of [¹¹C]CO₂ with MeMgBr followed by reduction with LiAlH₄, then reaction with HI. Distillation of the [¹¹C]alkyl iodides into a solution of hydrogen (4-nitrophenyl)methylphosphonate and cesium carbonate afforded the desired tracers in > 95% radiochemical purity, yields from [¹¹C]CO₂ of 1-3% and 1.7-15.1 GBq/mmol molar activities.

Keywords

Organophosphate; [¹¹C]sarin surrogate; [¹¹C]VX surrogate; acetylcholinesterase; [¹¹C]ethyl iodide; [¹¹C]isopropyl iodide

1. Introduction

Organophosphate (OP) compounds are a class of chemicals which were initially developed as insecticides. Their novel mechanism of toxicity and rapid effect, however, led to their further development into chemical warfare agents (CWAs). CWAs such as the V- (VX) and G-agents (sarin, soman) are non-discriminating neuropoisons that pose a threat to both military and civilian populations (Fig. 1). Toxicity in humans following OP exposure occurs mainly through the inactivation of acetylcholinesterase (AChE), the enzyme that hydrolyzes the neurotransmitter acetylcholine (ACh), which is responsible for proper function of muscle stimulation. At high exposure levels, inhibition of available AChE pools in the CNS causes a

Corresponding Author: Henry F. VanBrocklin, Department of Radiology and Biomedical Imaging, University of California – San Francisco, 185 Berry St. Suite 350, San Francisco, CA 94107. Phone: 415 353-4569, Fax:(415) 514-8242, Henry.Vanbrocklin@ucsf.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

rapid increase in ACh and triggers neurotoxic sequelae (Taylor, 2018). If administered soon after exposure, OP toxicity can be ameliorated using antidote combinations such as 2-pyridine aldoxime methyl iodide (2-PAM) and atropine (Fukuto, 1990; Sidell and Borak, 1992; Taylor, 2018; Voicu et al., 2010).

The mechanism of inhibition of AChE by an OP occurs through interaction with a serine residue in the active site concomitant with loss of a leaving group (Fig. 2). The resultant OP-AChE adduct is relatively stable leading to prolonged stimulation of post-synaptic receptors by ACh. The OP-AChE adduct can undergo reactivation by oximes (e.g., 2-PAM) that restores the enzyme activity or participate in a process called ‘aging,’ which results from phosphoester dealkylation and forms a methyl phosphonate anion permanently inactivating AChE. The stability (or lack thereof) of the OP-AChE adduct is dictated by the phosphoester group with the sarin-AChE adduct bearing an isopropyl ester undergoing aging in minutes, whereas the VX-AChE adduct bearing an ethyl ester ages over hours yet both result in the same OP-AChE adduct after the aging process. Due to this unique stepwise loss of the initial leaving group and possible aging of an esteratic moiety, placement of the isotopic label is critical to measure intact OP-AChE adduct or aged moiety.

Native ^{11}C -sarin was previously prepared (Prenant and Crouzel, 1990) but biological data was not reported, in part, due to the extreme toxicity and handling concerns with OP CWA agents. Recently, researchers have turned to the OP ‘surrogates’ (Chao et al., 2016; Chao et al., 2018; Fukuto and Metcalf, 1959; Meek et al., 2012) in which a *p*-nitrophenoxy (PNP) replaces the reactive fluorine or thiocholine ester leaving group of a CWA. PNP is an excellent leaving group ($\text{pK}_a \sim 7.2$) and is present on the potent anti-AChE molecule paraoxon. It confers safer handling due to low volatility and adds a chromophore that is important for analysis. The mechanism of inhibition of PNP-substituted surrogates was recently validated for the VX-surrogate in nonradioactive (cold) (Chao et al., 2016; Chao et al., 2018) and [^{18}F]-tracer (James et al., 2014) forms.

Although the interactions of ^{18}F -VX surrogate in wild-type rats showed rapid equilibration in body tissues (James et al., 2014) and retained the desired mechanism of AChE inactivation, in some instances [^{11}C]tracers can be an inherently better alternative for PET imaging, as these tracers would not introduce a second non-native chemical moiety to the OP surrogates. Integration of the carbon-11 into the phosphoester moiety of the OP would result in a viable PET OP imaging agent as this group is retained upon phosphorylation of AChE.

With the goal of preparing new ^{11}C -labeled PET tracers for evaluating the exposure mechanism of OP agents and reactivation therapies, we sought a radiosynthetic route to produce [^{11}C]VX and [^{11}C]sarin surrogates. As indicated, OP surrogates differ from the parent compounds by a PNP leaving group. The resultant [^{11}C]OP-surrogates, namely, 1-[^{11}C]ethyl, 4-nitrophenyl methylphosphonate ([^{11}C]2) and 2-[^{11}C]propan-yl, 4-nitrophenyl methylphosphonate ([^{11}C]3) have been reported to possess similar properties of inhibition, reactivation and adduct formulation as the parent VX and sarin compounds (Meek et al., 2012). We present the efficient radiosyntheses and purification protocols of [^{11}C]2 and [^{11}C]3 PET tracers for utilizing a common set of starting reagents.

2. Experimental

Materials.

All reagents and solvents (purchased and used as anhydrous) were obtained from Sigma-Aldrich (St. Louis, MO) and used without further purification unless otherwise noted. MeMgBr in diethyl ether (3M), diethyl ether, and LiAlH₄ in THF (1M) were obtained in Sure/Seal™ containers from Sigma-Aldrich. Containers were stored in a desiccator between uses and were used up to 10 times before loss of molar activity was noted. 4-Nitrophenyl hydrogen methylphosphonate **1**, VX surrogate **2** and sarin surrogate **3** were synthesized by literature procedures (Chao et al., 2016; Chao et al., 2018; Tawfik et al., 1993). The loop and valve used in this experiment were cleaned after each run by sequential washing with 10% citric acid (10 mL), water (10 mL) and acetone (10 mL), the system was then dried under a continuous flow of nitrogen for 20 minutes. Nitrogen flow was initiated 20 minutes prior to the start of synthesis to eliminate endogenous CO₂.

Analytical HPLC was performed using a Waters 590 LC pump (Midland, MA), connected in series to a Shimadzu SPD-UV-Visible detector (Columbia, MD) ($\lambda = 254$ nm) and a gamma counting in-line radiation flow detector (Model 105a, CRA; Berkeley, CA) with a Phenomenex Luna® 5 μ m C-18(2) 100 Å 250 × 4.6 mm LC column using an isocratic system of 40% acetonitrile in 60% 5 mM pH 6.8 phosphate buffer. Semi-preparative purification of tracer was performed using a Waters 600 LC pump (Milford, MA) connected in series to a Shimadzu SPD-UV-Visible detector (Columbia, MD) ($\lambda = 254$ nm) and a gamma counting in-line radiation flow detector (Model 105a, CRA; Berkeley, CA) with a Phenomenex Luna® 10 μ m C-18(2) 100 Å 250 × 10 semi-preparative HPLC column using an isocratic solvent system of 50% acetonitrile in 5 mM pH 6.8 phosphate buffer. HPLC chromatograms were acquired using SRI PeakSimple software (version 304 – Torrence, CA).

Radiosynthesis of 1-[¹¹C]ethyl, 4-nitrophenyl methylphosphonate ([¹¹C]2).

[¹¹C]CO₂ was cryotrapped in an aluminum tube charged with glass wool, submerged in liquid nitrogen. While the [¹¹C]CO₂ is being trapped, a Teflon tube (40 cm, 0.030" ID) at 0 °C was coated with 1 mL of 1M MeMgBr in ether (diluted with anhydrous ether from commercially available 3.0 M MeMgBr in ether). Nitrogen gas was used to lightly blow dry the ether (15-30 sec) and then the [¹¹C]CO₂ was delivered through the MeMgBr coated loop at a flow rate of 5 mL/min with nitrogen as the carrier gas while the loop was maintained at 0 °C. Once the activity had been transferred, the nitrogen flow was stopped and the loop was left at 0 °C for 90 sec. The activity was eluted off the loop with 0.2 M LiAlH₄ (1 mL) in THF. The solvent was then removed under a flow of nitrogen at 100 °C, and concentrated HI (300 μ L) was added at 0 °C. The reaction was then heated to 180 °C and distilled through P₂O₅ and ascarite traps in series into a vial containing **1** (5 mg, 23 μ mol) with Cs₂CO₃ (9-11 mg, 27-34 μ mol) in DMF (300 μ L). After approximately 4 min the distillation was ended and the reaction vial was heated to 115 °C for 5 min. The mixture was then cooled to room temperature, diluted with 20% acetonitrile in 0.1% ascorbic acid in water, and injected onto a semi-prep HPLC column (C18(2) 250 × 10 mm, 50:50 acetonitrile/0.1% ascorbic acid, 6 mL/min, 254 nm) for purification. The desired peak was collected ($t_R = 5.2$ min), diluted to 30 mL with 10 mM pH 6.8 phosphate buffer and loaded onto a C-18 light Sep-Pak. The Sep-

Pak was washed with an addition 5 mL of phosphate buffer and eluted with 500 μ L acetonitrile. The acetonitrile was concentrated to 100 μ L and reconstituted to give a solution of 10% acetonitrile in 10 mM pH 6.8 phosphate buffered saline. Molar activity was accessed using analytical HPLC on a Luna C18(2) column (250 \times 2.6 mm, 40% acetonitrile/60% 5 mM pH 6.8 phosphate buffer, 1 mL/min, 254 nm). This process yielded [^{11}C]2 in 2.8 % \pm 1.5% decay corrected yield (EOB; 45 min) from [^{11}C]CO₂ with a molar activity of 1.7 \pm 0.6 GBq/ μ mol (42 \pm 16 Ci/mmol, n = 6, 55 min).

Radiosynthesis of 2-[^{11}C]propyl (4-nitrophenyl)methylphosphonate ([^{11}C]3).

The exact same procedure as [^{11}C]2 was used with the following exceptions: once the [^{11}C]CO₂ had been transferred into the MeMgBr coated loop, the nitrogen flow was stopped and the loop was warmed to 25 $^{\circ}\text{C}$ for 5 min. The reaction was loaded on the HPLC as described above. The desired peak was collected (t_{R} = 6.1 min), diluted to 30 mL with 10 mM pH 6.8 phosphate buffer and loaded onto a C-18 light Sep-Pak. The Sep-Pak was washed with an addition 5 mL of phosphate buffer and eluted with 500 μ L acetonitrile. The acetonitrile was concentrated to 100 μ L and reconstituted to give a solution of 10% acetonitrile in 10 mM pH 6.8 phosphate buffered saline. Molar activity was accessed using analytical HPLC on a Luna C18(2) column (250 \times 2.6 mm, 40% acetonitrile/60% 5 mM pH 6.8 phosphate buffer, 1 mL/min, 254 nm). This process yielded [^{11}C]3 in 1.04 % \pm 0.96% decay corrected yield (EOB; 50 min) from [^{11}C]CO₂ with a molar activity of 15.1 \pm 6.9 GBq/ μ mol (409 \pm 187 Ci/mmol, n = 6, 60 min).

3. Results and Discussion

Initially, a transesterification reaction between [^{11}C]-labeled alcohols and *bis*-(*p*-nitrophenyl) methylphosphonate (Tawfik et al., 1993) was attempted to prepare the labeled surrogates of VX and sarin. However, production of the corresponding alcohols required a strong reducing agent and workup with water that caused hydrolysis of the product due to surplus Cs₂CO₃ present. Due to this issue, a different approach was needed to yield the desired [^{11}C]OP surrogates. One alternate approach was to react alkyl iodides with a phosphate oxyanion to introduce a labeled ester group rather than couple to an alcohol. The labeled surrogates could then be accessed via the readily available methyl phosphonic acid precursor **1** (Fig. 3). In general, while [^{11}C]methyl iodide is a common precursor for carbon-11 syntheses, there are very few reliable methods for the production of [^{11}C]ethyl iodide and [^{11}C]isopropyl iodide. (Långström et al., 1986; Zhang et al., 2006) Therefore, an investigation was undertaken to achieve these important labeled synthons.

In a previous report microfluidics was used to produce [^{11}C]labeled ethyl and isopropyl iodide (Zhang et al., 2006). This was achieved through temperature control of a loop coated with MeMgBr. Low temperatures ($-11\text{ }^{\circ}\text{C}$) favored mono-addition of Grignard reagent to yield the ethyl derivative, while warming the loop (25 $^{\circ}\text{C}$) afforded a second addition of Grignard to form the isopropyl product. This temperature-dependent approach was adapted for use with a loop setup by employing a six-way Rheodyne 7720 valve (Fig. 4). The loop was attached to allow flow either from a syringe port or from the [^{11}C]CO₂ feed line from the cyclotron. A positive pressure of nitrogen was initially applied through both of these

lines to minimize contamination by cold CO₂ gas. Temperature of the loop was controlled using either an ice or warm water bath, depending on the desired reaction temperature. Temperature control, as in the previous work, was essential for production of one or the other desired alkyl iodides.

Selection of the mono- and bis-addition of MeMgBr was controlled through changes in temperature and reaction time. Mono-addition of the Grignard reagent was performed by first coating the loop with MeMgBr at 0 °C. Flow of [¹¹C]CO₂ in nitrogen carrier was used to load the loop. The reaction was held at 0 °C for 90 s. Subsequent rinsing of the loop with a THF solution of LiAlH₄ gave [¹¹C]ethanol that was converted into the major product [¹¹C]ethyl iodide by heating with HI. Initial Grignard reactions were conducted at -11 °C. However, when the temperature was raised from -11 °C to 0 °C, to simplify the reaction setup, double Grignard addition occurred, albeit [¹¹C]ethyl iodide still predominated as the primary product at this temperature. [¹¹C]isopropyl iodide was selectively produced via the same general method as [¹¹C]ethyl iodide with two minor process changes. Following the transfer of the [¹¹C]CO₂ to the loop, the loop was moved into a 25 °C water bath and reacted for 5 min rather than 90 s. The higher temperature and longer time enabled more [¹¹C]isopropanol to be produced versus [¹¹C]ethanol. HPLC analysis (Fig. 5), of the iodides, collected by distillation, confirmed that the increase in reaction temperature favored the formation of the isopropyl product, however, significant amounts of methyl, ethyl and isopropyl iodides were seen in each reaction mixture.

Reaction of the [¹¹C]ethyl- or [¹¹C]isopropyl iodide preparation with **1** and Cs₂CO₃ under basic conditions gave a mixture of [¹¹C]**2** and [¹¹C]**3** along with labeled byproducts that may include the [¹¹C]alkyl alcohols and labeled hydrolyzed OP. Neutralization of the reactions with NaH₂PO₄ and injection onto the HPLC was carried out rapidly to reduce hydrolysis of the product in the basic reaction solution. Semi-preparative HPLC (Fig. 5) afforded the purified [¹¹C]VX or [¹¹C]sarin surrogates, [¹¹C]**2** and [¹¹C]**3**, respectively. The purified products were concentrated by solid phase extraction on a C-18 light Sep-Pak. Elution with acetonitrile, concentration and dilution with phosphate buffered saline gave the 10% acetonitrile/ PBS formulation that was used in preclinical studies. Final decay corrected yields for [¹¹C]**2** and [¹¹C]**3** were 2.8 % ± 1.5% and 1.04 ± 0.96% with molar activities of 1.7 ± 0.6 GBq/μmol and 15.1 ± 6.9 GBq/μmol, respectively. Despite suitable quantities of the [¹¹C]ethyl- or [¹¹C]isopropyl iodide the low yields of the final products were believed to be a function of the reaction of the iodides with the OP intermediate and solution stability of the OP product once formed. It is interesting to note that in spite of the increase in isopropyl iodide formation in the warm loop reaction, [¹¹C]**2** appears to dominate in the OP coupling reaction. This may be due to the lower stability of the isopropyl OP surrogates, as has been shown previously. (Hayes et al., 2018) While iodide optimization was not undertaken in this study, there may be efficiencies and yield gained by reducing the time necessary to conduct the synthetic manipulations, adjusting the loop temperature to 0 °C or 25 °C at the start of the desired iodide synthesis, adjusting precursor and reagent quantities, or considering alternate loop materials and sizes. (Matarrese et al., 2002; Wadsak et al., 2007)

Lower molar activities of [¹¹C]**2** and [¹¹C]**3** were likely due to presence of cold CO₂ introduced that was present in the reactor system, or while diluting the MeMgBr to the

desired concentration. Thus, care should be taken during the setup of the reaction to minimize the introduction of exogenous CO₂. Dilution of solutions under inert atmosphere would be desirable and reduce atmospheric CO₂ exposure. In the current process the syringe port is opened several times to atmosphere. Introducing multiple port valve attached to the syringe port could allow introduction of the precursors and reagents without introducing CO₂. These improvements may increase the molar activity. The [¹¹C]VX and [¹¹C]Sarin surrogates interact with the high capacity acetylcholinesterase enzyme system so the reported molar activities are adequate for initial the imaging studies.

Importantly, the radiosynthetic method is able to provide both [¹¹C]ethyl- and [¹¹C]isopropyl-iodides using the same reagents and by the same reaction, whereby the loop reaction using cooler temperature and shorter reaction time favors the formation of [¹¹C]ethanol, and higher temperature and longer reaction time favors [¹¹C]isopropanol preparation that are subsequently transformed to their respective iodide forms.

4. Conclusions

New organophosphate carbon-11 labeled surrogates of VX and sarin were prepared. To achieve this, a loop synthesis method was developed for the production of both [¹¹C]ethyl and [¹¹C]isopropyl iodides using the same reagents. The selective formation of one radiolabeled alkyl iodide fragment over the other was effectively achieved through control of reaction temperature and time. Sufficient amounts of the radiolabeled VX and sarin surrogates tracers [¹¹C]2 and [¹¹C]3, respectively tracers from production are obtained to enable testing of biological properties. The divergent radiolabeling method described in this paper for the production of [¹¹C]ethyl and [¹¹C]isopropyl iodide is considered generally useful for application to the formation of a broad spectrum of carbon-11 PET tracers.

Acknowledgements

This work was supported by the CounterACT Program, National Institutes of Health Office of the Director (NIH OD), and the National Institute of Neurological Disorders and Stroke (NINDS), Grant Award Number U01NS092495. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

References

- Chao CK, Ahmed SK, Gerdes JM, Thompson CM, 2016 Novel Organophosphate Ligand O-(2-Fluoroethyl)-O-(p-Nitrophenyl)Methylphosphonate: Synthesis, Hydrolytic Stability and Analysis of the Inhibition and Reactivation of Cholinesterases. *Chem Res Toxicol* 29, 1810–1817. [PubMed: 27551891]
- Chao CK, Balasubramanian N, Gerdes JM, Thompson CM, 2018 The inhibition, reactivation and mechanism of VX-, sarin-, fluoro-VX and fluoro-sarin surrogates following their interaction with HuAChE and HuBuChE. *Chem Biol Interact* 291, 220–227. [PubMed: 29920286]
- Fukuto TR, 1990 Mechanism of action of organophosphorus and carbamate insecticides. *Environ. Health Perspect.* 87, 245–254. [PubMed: 2176588]
- Fukuto TR, Metcalf RL, 1959 The Effect of Structure on the Reactivity of Alkylphosphonate Esters. *Journal of the American Chemical Society* 81, 372–377.
- Hayes TR, Thompson CM, Blecha JE, Gerdes JM, VanBrocklin HF, 2018 Radiosynthesis of O-(1-[¹⁸F]fluoropropan-2-yl)-O-(4-nitrophenyl)methylphosphonate: A novel PET tracer surrogate of

- sarin. *Journal of Labelled Compounds and Radiopharmaceuticals* 61, 1089–1094. [PubMed: 30347484]
- James SL, Ahmed SK, Murphy S, Braden MR, Belabassi Y, VanBrocklin HF, Thompson CM, Gerdes JM, 2014 A novel fluorine-18 beta-fluoroethoxy organophosphate positron emission tomography imaging tracer targeted to central nervous system acetylcholinesterase. *ACS Chem Neurosci* 5, 519–524. [PubMed: 24716794]
- Långström B, Antoni G, Gullberg P, Halldin C, Någren K, Rimland A, Svård H, 1986 The synthesis of 1-11C-labelled ethyl, propyl, butyl and isobutyl iodides and examples of alkylation reactions. *International Journal of Radiation Applications and Instrumentation. Part A. Applied Radiation and Isotopes* 37, 1141–1145.
- Matarrese M, Sudati F, Soloviev D, Todde S, Turolla EA, Kienle MG, Fazio F, 2002 Automation of [11C]acetyl chloride syntheses using commercially available 11C-modules. *Applied Radiation and Isotopes* 57, 675–679. [PubMed: 12433041]
- Meek EC, Chambers HW, Coban A, Funck KE, Pringle RB, Ross MK, Chambers JE, 2012 Synthesis and in vitro and in vivo inhibition potencies of highly relevant nerve agent surrogates. *Toxicol Sci* 126, 525–533. [PubMed: 22247004]
- Prenant C, Crouzel C, 1990 Synthesis of [11C]-sarin. *Journal of Labelled Compounds and Radiopharmaceuticals* 28, 645–651.
- Sidell FR, Borak J, 1992 Chemical warfare agents: II. Nerve agents. *Ann Emerg Med* 21, 865–871. [PubMed: 1610046]
- Tawfik DS, Eshhar Z, Bentolila A, Green BS, 1993 1,8-Diazabicyclo[5.4.0]undecene Mediated Transesterification of p-Nitrophenyl Phosphonates: A Novel Route to Phosphono Esters. *Synthesis* 1993, 968–972.
- Taylor P, 2018 Anticholinesterase Agents, in: Brunton LL, Hilal-Dandan R, Knollmann BC (Eds.), *Goodman & Gilman's: The Pharmacological Basis of Therapeutics*, 13e. McGraw-Hill Education, New York, pp. 163–176.
- Voicu VA, Thiermann H, Rdulescu F, Mircioiu C, Miron DS, 2010 The toxicokinetics and toxicodynamics of organophosphonates versus the pharmacokinetics and pharmacodynamics of oxime antidotes: biological consequences. *Basic and Clinical Pharmacology and Toxicology* 106, 73–85. [PubMed: 19961476]
- Wadsak W, Mien L-K, Ettliger Dagmar E, Lanzenberger R, Haeusler D, Dudczak R, Kletter K, Mitterhauser M, 2007 Simple and fully automated preparation of [carbonyl-11C]WAY-100635. *Radiochimica Acta*, p. 417.
- Zhang M-R, Ogawa M, Yoshida Y, Suzuki K, 2006 Selective synthesis of [2-11C]2-iodopropane and [1-11C]iodoethane using the loop method by reacting methylmagnesium bromide with [11C]carbon dioxide. *Applied Radiation and Isotopes* 64, 216–222. [PubMed: 16194603]

Highlights

- Loop preparation of $[^{11}\text{C}]\text{Et-I}$ and $[^{11}\text{C}]\text{iPr-I}$ from $[^{11}\text{C}]\text{CO}_2$ and common reagents was developed.
- Increase in Grignard temperature/time shifted the intermediate from $[^{11}\text{C}]\text{EtI}$ to $[^{11}\text{C}]\text{iPrI}$.
- $[^{11}\text{C}]\text{alkyl iodide}$ reaction with $(4\text{-NO}_2\text{PhO})(\text{Me})\text{P}(\text{O})\text{O}^-\text{Cs}^+$ affords VX and sarin OP surrogates.




Fig. 1.
Structures of common chemical warfare agents.




Fig. 2. Inhibition of acetylcholinesterase by OP CWAs and the aging or reactivation processes.




Fig. 3.
Synthesis of PET tracers [¹¹C]**2** and [¹¹C]**3**.




Fig. 4. Schematic for the HPLC injection port used in the loop synthesis of [^{11}C]ethyl iodide and [^{11}C]isopropyl iodide. A. Configuration for the introduction of the MeMgBr reagent and release of the ^{11}C labeled compound. B. Configuration for the introduction of the ^{11}C from the cyclotron.




Fig. 5. Reverse phase HPLC radio-chromatograms of the crude $[^{11}\text{C}]$ intermediates and products. $[^{11}\text{C}]$ ethyl iodide (Luna C18(2) analytical column, 75% acetonitrile/25% 10 mM NH_4OAc H_2O , 1 mL/min) and $[^{11}\text{C}]$ isopropyl iodide (Luna C18(2) analytical column, 70% acetonitrile/30% 10 mM NH_4OAc H_2O , 2 mL/min).